Результаты поиска

Determining Risk Factors Associated with Cardiovascular Complications in Patients with Acute Leukemia: A Systematic Review.

BackgroundPatients with acute leukemia (AL) are at heightened risk of cardiovascular complications due to both disease-related and treatment-related factors. These complications include heart failure, arrhythmias, myocardial infarction, and thromboembolic events which may significantly impact morbidity and mortality.ObjectiveTo identify the risk factors contributing to cardiovascular complications in patients with acute leukemia.MethodsThis systematic review was conducted according to the PRISMA reporting guideline. Multiple databases including PubMed, Scopus, IEEE Xplore, the Cochrane Library

Exploring the Emerging Association Between Immune Checkpoint Inhibitors and Thrombosis.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their association with thrombosis presents significant clinical challenges. Patients with cancer already exhibit elevated risks for venous thromboembolism and arterial thrombosis, with treatment modalities like chemotherapy further exacerbating this risk. Emerging evidence suggests that ICIs contribute to thrombotic events through multifactorial mechanisms, including immune dysregulation, T cell activation, endothelial dysfunction, elevated tissue factor expression, and impaired fibrinolysis. Additional risk factors

Xerostomia due to systemic disease: a review of 20 conditions and mechanisms.

Xerostomia is a common complaint of nearly half of the elderly population and about one-fifth of younger adults. It causes several signs and symptoms, and compromise oral functions and health-related quality-of-life. Multiple reasons are proposed to describe the etiology of xerostomia such as local factors, psychogenic factors, and systemic diseases. In order to manage xerostomia effectively, identification of the main causality is mandatory. The aim of this review was to present systemic diseases leading to xerostomia with their mechanisms of action. We used various general search engines and

Monoclonal Antibodies Approved for Cancer Therapy

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… inflammatory response syndrome, SJS Stevens-Johnson syndrome, TEN toxic epidermal necrolysis, TLS tumor lysis syndrome, URTI upper respiratory tract infection, VEGF vascular endothelial growth factor, VEGFR - 2 vascular endothelial growth factor receptor 2 a Nomenclature: mAbs of murine origin are given … Up to the end of 2012, postmarketing reports from Europe listed eight cases of respiratory disorders, 11 cases of cutaneous reactions, 11 reports of infections, and eight cases of systemic inflammatory response syndrome (SIRS) (Chap. 10.1007/978-3-319-30472-4_1, section “Systemic Inflammatory Response …

Множественный склероз педиатрии (POMS) и эпилепсия: исследование этиологической сложности - результаты из опыта одного центра.

В этой статье рассматривается сложная взаимосвязь между припадками, эпилепсией и множественным склерозом (МС) у педиатрических пациентов на основе подробных результатов исследования, проведенного в одном центре. Справочная информация: Хотя множественный склероз в первую очередь признается в качестве заболевания, порождаемого взрослыми, его распространенность у детей сопряжена с особыми проблемами, особенно связанными с расстройствами припадков. Методы: Мы провели обзор 120 Число пациентов педиатрии, прошедших оценку 7 годы; six (из них)5%) опытных изъятий (включая one случай острого эпилептиче

Разъяснение роли GRK2: от иммунного регулирования к терапии рака.

G белковые рецепторы (GPCR) представляют собой наиболее заметное семейство мембранных белков. В противоположность этому, G-белковые рецепторы (GRKs) играют ключевую роль в быстрой десенсибилизации ГПКР. GRK2 является особенно важным членом семьи GRK. Недавние исследования показали, что GRK2 в первую очередь регулирует функции иммунных клеток и гомеостаз через десенсибилизацию рецептора. За последнее десятилетие был достигнут существенный прогресс в разъяснении роли GRK2 в различных заболеваниях человека. В частности, GRK2 имеет отношение к целому ряду аутоиммунных расстройств, включая ревматуи

EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients.

BackgroundThe coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role in pathophysiology, and simple prognosticators may help to optimize allocation of limited resources. Endothelial activation and stress index (EASIX) is a validated predictor of endothelial complications and outcome after allogeneic stem cell transplantation. Aim of this study was to test if EASIX could predict life-threatening complications in pati

Are patients with cancer with sepsis and bacteraemia at a higher risk of mortality? A retrospective chart review of patients presenting to a tertiary care centre in Lebanon.

ObjectiveMost sepsis studies have looked at the general population. The aim of this study is to report on the characteristics, treatment and hospital mortality of patients with cancer diagnosed with sepsis or septic shock.SettingA single-centre retrospective study at a tertiary care centre looking at patients with cancer who presented to our tertiary hospital with sepsis, septic shock or bacteraemia between 2010 and 2015.Participants176 patients with cancer were compared with 176 cancer-free controls.Primary and secondary outcomesThe primary outcome of this study was the in hospital mortality

Совпадение в полном тексте источника
… inflammatory response syndrome (SIRS) criteria in this subset of population. … Scand J Trauma Resusc Emerg Med 2009 ; 17 : 67 10.1186/1757-7241-17-67 20035633 PMC2806258 22 Kaukonen KM , Bailey M , Pilcher D Systemic inflammatory response syndrome criteria in defining severe sepsis . …

A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.

BackgroundCytokine release triggered by a hyperactive immune response is thought to contribute to severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2)-related respiratory failure. Bruton tyrosine kinase (BTK) is involved in innate immunity, and BTK inhibitors block cytokine release. We assessed the next-generation BTK inhibitor zanubrutinib in SARS-CoV-2-infected patients with respiratory distress.MethodCohort 1 had a prospective, randomized, double-blind, placebo-controlled design; cohort 2 had a single-arm design. Adults with SARS-CoV-2 requiring hospitalization (without mechanica

Noninfectious pulmonary complications of haematopoietic stem cell transplantation.

Haematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of malignant and nonmalignant conditions. Pulmonary complications, both infectious and noninfectious, are a major cause of morbidity and mortality in patients who undergo HSCT. Recent advances in prophylaxis and treatment of infectious complications has increased the significance of noninfectious pulmonary conditions. Acute lung injury associated with idiopathic pneumonia syndrome remains a major acute complication with high morbidity and mortality. On the other hand, bronchiolitis obliterans syndrome is

UEG Week 2017 Oral Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Evaluating clinical heterogeneity in relapsing polychondritis through unsupervised cluster analysis.

BACKGROUND: As a rare autoimmune disease, relapsing polychondritis (RP) exhibits individual variations in clinical manifestations, treatment response and prognosis. To date, no biomarkers have been implemented to clinical practice.This study aimed to apply cluster analysis to identify the clinical phenotype, clarify their prognosis predictor, and monitor treatment decisions to improve the outcomes of patients. METHODS: A total of 135 RP patients hospitalized in two centers from January 2005 to December 2024 were involved in the study.The K-means clustering algorithm was used as the core clust

Ход работы 34th Симпозиум ESVN-ECVN 23rd-24th сентябрь 2022.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Translating IL-6 biology into effective treatments.

In 1973, IL-6 was identified as a soluble factor that is secreted by T cells and is important for antibody production by B cells. Since its discovery more than 40 years ago, the IL-6 pathway has emerged as a pivotal pathway involved in immune regulation in health and dysregulation in many diseases. Targeting of the IL-6 pathway has led to innovative therapeutic approaches for various rheumatic diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still's disease, giant cell arteritis and Takayasu arteritis, as well as other conditions such as Castleman disease and

Purinergic Signalling: Therapeutic Developments.

Purinergic signalling, i.e., the role of nucleotides as extracellular signalling molecules, was proposed in 1972. However, this concept was not well accepted until the early 1990's when receptor subtypes for purines and pyrimidines were cloned and characterised, which includes four subtypes of the P1 (adenosine) receptor, seven subtypes of P2X ion channel receptors and 8 subtypes of the P2Y G protein-coupled receptor. Early studies were largely concerned with the physiology, pharmacology and biochemistry of purinergic signalling. More recently, the focus has been on the pathophysiology and the

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation.

BackgroundCytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms.MethodsThis study examined the plasma cytokine profiles of patients with essential thrombocythemia, primary myelofibrosis, polycythemia vera and of healthy subjects, and analyzed correlations with JAK2 V617F status and clinical-hematological parameters.ResultsThe proinflammatory cytokine levels were increased in myeloproliferative neoplasm patients, and the presence of the JA

Доклад о деле: Синдром Свободного селезённого повреждения перед началом множественных склерозов.

Синдром обратимого селенического поражения часто ассоциируется с инфекциями системной и центральной нервной системы. Неизвестно, может ли инфекция, связанная с возникновением обратимого синдрома селениального поражения, сыграть какую-либо роль в последующем развитии множественного склероза. Отчет по делу. Результаты: 27-летняя женщина разработала связанный с инфекцией обратимый синдром селезенки. Диагностические результаты не выявили конкретного вида инфекции, а выявили признаки потенциального воздействия на автоиммунитет. Через 32 месяца после первоначального представления появились новые кли

Pharmacological treatment options for mast cell activation disease.

Mast cell activation disease (MCAD) is a term referring to a heterogeneous group of disorders characterized by aberrant release of variable subsets of mast cell (MC) mediators together with accumulation of either morphologically altered and immunohistochemically identifiable mutated MCs due to MC proliferation (systemic mastocytosis [SM] and MC leukemia [MCL]) or morphologically ordinary MCs due to decreased apoptosis (MC activation syndrome [MCAS] and well-differentiated SM). Clinical signs and symptoms in MCAD vary depending on disease subtype and result from excessive mediator release by MC

Host impairments in patients with neoplastic diseases.

Healthy individuals possess an immune system comprising physical barriers, innate and acquired immunity as well as the indigenous microflora that populate the body surfaces. The immune system maintains constant vigilance over the body at the cellular level as well as at the interface between the host integument and the resident microflora. However, neoplastic diseases and their treatment often lead to impaired immunity resulting in an increased risk of infections due to viruses, bacteria, fungi, and protozoa. This chapter explores the various aspects of host impairment focusing on the componen

The phenotypic and genetic association between endometriosis and immunological diseases.

STUDY QUESTION: Is there an increased risk of immunological diseases among endometriosis patients, and does a shared genetic basis contribute to this risk? SUMMARY ANSWER: Endometriosis patients show a significantly increased risk of autoimmune, autoinflammatory, and mixed-pattern diseases, including rheumatoid arthritis, multiple sclerosis, coeliac disease, osteoarthritis, and psoriasis, with genetic correlations between endometriosis and osteoarthritis, rheumatoid arthritis, and multiple sclerosis, and a potential causal link to rheumatoid arthritis. WHAT IS KNOWN ALREADY: The epidemiologi